O008/#785 A multicenter, open-label, randomized, phase 3 study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer: study 309/keynote-775
Makaleler > Tam Makale · 2021
Yazarlar: V. Makker, N. Colombo, A. Casado Herráez, A. Santin, E. Colomba, D. Miller, K. Fujiwara, S. Pignata, S. Baron-Hay, I. Ray-Coquard, R. Shapira, K. Ushijima, J. Sakata, K. Yonemori, Y.M. Kim, E.M. Guerra, U.A. Sanli, M. Mccormack, J. Huang, A.D. Smith
International Journal of Gynecological Cancer, Uluslararası, Wos, 2021, cilt 31, ss A4-A5